-
Osimertinib, sold
under the
brand name Tagrisso, is a
medication used to
treat non-small-cell lung
carcinomas with
specific mutations. It is a third-generation...
- inhibitor.[medical
citation needed]
Brigatinib could overcome resistance to
osimertinib conferred by the EGFR C797S
mutation if it is
combined with an anti-EGFR...
-
randomized (2:2:1) to
receive lazertinib in
combination with amivantamab,
osimertinib monotherapy, or
lazertinib monotherapy (an
unapproved regimen for non-small...
-
available products include velpatasvir/sofosbuvir, sofosbuvir/daclatasvir,
osimertinib, crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib...
-
cetuximab for
colon cancer. More
recently AstraZeneca has
developed Osimertinib, a
third generation tyrosine kinase inhibitor. Many
therapeutic approaches...
-
development of cancer. Therefore,
kinase inhibitors, such as
imatinib and
osimertinib, are
often effective cancer treatments. Most
tyrosine kinases have an...
-
Amivantamab is
being investigated in
combination with
lazertinib versus osimertinib; and in
combination with carboplatin-pemetrexed
chemotherapy compared...
- Ali SM, et al. "Aumolertinib with
chemotherapy or
alone compared with
osimertinib in
patients with EGFR-mutant non–small-cell lung
cancer (TREBLE)". Journal...
-
inhibitors are outcompeted;
irreversible covalent inhibitors such as
osimertinib can
overcome this resistance. Over 50% of
acquired resistance to EGFR...
-
Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast Rosuvastatin...
